Vanguard Group Inc. Boosts Stock Position in Theravance Biopharma, Inc. $TBPH

Key Points

• Vanguard Group Inc. increased its stake in Theravance Biopharma by 3.5%, acquiring an additional 69,919 shares, bringing its total ownership to approximately 4.16% valued at $18.6 million.
• Several analysts have upgraded Theravance Biopharma, with Zacks Research changing its rating from "hold" to "strong-buy," and a consensus target price now set at $21.33.
• Theravance Biopharma's stock was recently priced at $13.88, with a market capitalization of $699 million, reflecting a 0.6% decrease in share value.

Vanguard Group Inc. lifted its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 3.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,080,463 shares of the biopharmaceutical company's stock after purchasing an additional 69,919 shares during the quarter. Vanguard Group Inc. owned 4.16% of Theravance Biopharma worth $18,579,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. R Squared Ltd raised its holdings in Theravance Biopharma by 636.6% in the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 10,822 shares during the period. Jefferies Financial Group Inc. acquired a new position in shares of Theravance Biopharma during the 1st quarter worth approximately $191,000. XTX Topco Ltd lifted its position in shares of Theravance Biopharma by 20.8% during the 1st quarter. XTX Topco Ltd now owns 19,759 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 3,403 shares in the last quarter. GSA Capital Partners LLP grew its stake in Theravance Biopharma by 11.9% in the 1st quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company's stock valued at $1,628,000 after acquiring an additional 19,363 shares during the period. Finally, Brookwood Investment Group LLC purchased a new stake in Theravance Biopharma in the 1st quarter worth $188,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TBPH shares. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. BTIG Research lifted their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, June 27th. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research note on Tuesday, June 17th. Finally, Zacks Research upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 15th. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat.com, Theravance Biopharma currently has an average rating of "Strong Buy" and a consensus target price of $21.33.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the transaction, the senior vice president owned 326,918 shares of the company's stock, valued at $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.90% of the company's stock.

Theravance Biopharma Price Performance

Shares of TBPH traded down $0.03 during mid-day trading on Wednesday, reaching $13.81. The stock had a trading volume of 340,838 shares, compared to its average volume of 281,717. Theravance Biopharma, Inc. has a 52-week low of $7.88 and a 52-week high of $14.55. The firm has a market cap of $695.59 million, a price-to-earnings ratio of 57.58 and a beta of 0.05. The business's fifty day moving average is $11.93 and its 200 day moving average is $10.35.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.